Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum]
Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319– 1332. The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast (which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252 by the manufact...
Enregistré dans:
Auteurs principaux: | Dubin C, Del Duca E, Guttman-Yassky E |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e29c8d896dc34349a1aa8ece5789d99b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy of Dupilumab for Atopic Dermatitis According to Clinical Course and Clinical Findings: A Multicentre Retrospective Study
par: Takeshi Nakahara, et autres
Publié: (2021) -
A COMPARATIVE STUDY ON EFFECT OF ENDOGENOUS AND EXOGENOUS ECZEMA ON QUALITY OF LIFE
par: Najia Ahmed, et autres
Publié: (2019) -
El eczema infantil desde el punto de vista pediátrico - dermatológico y de la alergia
par: SEPULVEDA R,DARIO
Publié: (1949) -
El Eczema infantil desde el punto de vista pediátrico-dermatológico y de la alergia: II Tratamiento y profilaxis
par: SEPULVEDA R,DARIO
Publié: (1949) -
Nasal Polyps in Children: The Early Origins of a Challenging Adulthood Condition
par: Maria E. Di Cicco, et autres
Publié: (2021)